Obalon Therapeutics, Inc. (OBLN) News
Obalon Therapeutics, Inc. (OBLN)
Today's Latest Price: $6.02 USD
Updated Jan 22 4:00pm
Add OBLN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 186 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
StocksNews Articles for OBLN
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest OBLN News From Around the Web
Below are the latest news stories about Obalon Therapeutics Inc that investors may wish to consider to help them evaluate OBLN as an investment opportunity.
Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losersGainers: Obalon Therapeutics (OBLN) +181%, Caladrius Biosciences (CLBS) +137%, Titan Medical (TMDI) +36%, Tiziana Life Sciences (TLSA) +31%, Gritstone Oncology (GRTS) +12%.Losers: BioLineRx (BLRX) -24%, AcelRx Pharmaceuticals (ACRX) -17%, Bionano Genomics (BNGO) -16%, Jaguar Health (JAGX) -13%, Acer Therapeutics (ACER) -11%.... |
Obalon is up 76% after announcing merger with ReShape LifesciencesObalon Therapeutics (OBLN) is up ~75.8% after announcing a merger agreement with ReShape Lifesciences in an all-stock deal whereby the existing ReShape stockholders will have a majority of the ownership of the combined company that will be renamed as ReShape Lifesciences Inc.Following the completion of the merger, ReShape Lifesciences will trade... |
Obalon Therapeutics stock soars to lead all gainers on massive volume after ReShape merger dealShares of Obalon Therapeutics Inc. blasted six-fold higher on massive volume in afternoon trading Wednesday, after the weight loss technologies company announced an agreement to merge with weight loss solutions company ReShape Lifesciences Inc. . Obalon's stock rose 503.4% toward the highest close since JUne 2019, while trading volume soared to 395.4 million shares, compared with the full-day average of about 626,000 shares. The stock was the biggest gainer and most active on major U.S. exchanges on Wednesday. ReShape shares, which currently trade over the counter, rose 155%. When the merger is completed, ReShape shareholders will own 51% of the combined entity, and the company will be renamed Reshape Lifesciences Inc. and will trade on the Nasdaq under the ticker symbol "RSLS." "We are... |
Is Obalon Therapeutics, Inc. (OBLN) A Good Stock To Buy?After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […] |
New Comprehensive Report on Obesity Intervention Devices Market 2020-2027| EnteroMedics, Apollo Endosurgery, Cousin Biotech, Aspire Bariatrics, Obalon TherapeuticsHealthCare Intelligence Markets unravels its new study titled Obesity Intervention Devices Market. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data. For an effective business outlook, it studies North America, Latin America, Asia-Pacific, |
Obalon Announces Third Quarter 2020 Financial ResultsSAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the suspension of operations in the second quarter of 2020. Net loss for the third quarter of 2020 was $1.6 million, compared to $3.7 million for the third quarter of 2019. Net loss per share for the third quarter of 2020 was $0.20, compared to $0.61 for the third ... |
Obalon Announces Second Quarter 2020 Financial ResultsSAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue reserves as a result of suspending business operations at the company-branded retail treatment centers. Net loss for the second quarter of 2020 was $4.2 million, compared to $6.8 million for the second quarter of 2019. Net loss per share for the second quart... |
Obalon Announces First Quarter 2020 Financial Results and Business UpdateSAN DIEGO, June 19, 2020 -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric. |
William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as DirectorObalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position. To assist the Company in the transition, Mr. Plovanic has agreed to remain as President and CEO through completion and filing of Obalon’s Form 10-Q for the quarter ended March 31, 2020 (the “Quarterly Report”). |
Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric BalloonsObalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity provided further clarification that it’s gas-filled balloon is not the subject of the April 27, 2020 letter issued by the FDA to health care providers warning of serious potential risks, including deaths, associated with the use of liquid-filled intragastric balloons. The Obalon swallowable, gas-filled balloon system utilizes a very different design and technology than the liquid-filled balloons cited now in four FDA letters to health care providers. |